R&D
DiaMedica’s novel biologic basal dilator: Bringing hope to p...
pharmaphorum spoke with DiaMedica’s CEO, Rick Pauls, about the company's efforts in preeclampsia, early-onset preeclampsia, and ischaemic stroke.
Digital
Controlling AI hallucinations: Building evidence-based trust...
When it comes to GenAI, industry must demand evidence-grounded systems that prioritise verifiable clinical data and rigorous human oversight.
Market Access
Capital discipline in biotech: Building enduring companies w...
Capital depends on the strength of the science, the quality of execution, and the ability to deliver on milestones as planned.
R&D
Sponsored
12 Questions with Faruk Uzman
Find out more about Faruk Uzman, VP EMEA at Boston Scientific, in a new 12 Questions With.
Oncology
From promise to practice: What must happen next for genetic ...
The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
